Test Price
1,900 AED✅ Home Collection Available
Minimal Residual Disease (MRD) Analysis for B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Executive Summary & Core Metrics
Precision MRD Quantification for Informed Treatment Decisions
This ISO‑certified multiparametric flow cytometry assay delivers 99.9% diagnostic sensitivity, detecting leukemic cells at or below 0.01% (10⁻⁴) threshold in bone marrow aspirates. The test enables accurate risk stratification, guides chemotherapy intensification or de‑escalation, and informs stem cell transplant timing for B‑ALL patients. Hospital extraction is strictly required; all samples are processed under validated cold‑chain conditions (18–22°C) at our Dubai Healthcare City laboratory. Direct insurance verification is available via WhatsApp at +971 54 548 8731.
Interpretation is provided in the context of the patient’s immunophenotype, clinical history, and concurrent therapy. Results are reviewed by a DHA‑licensed specialist before release, and complimentary post‑test tele‑guidance is offered to all referring physicians.
Test Overview & Methodology
Minimal Residual Disease (MRD) analysis using multiparametric flow cytometry is the established post‑induction surveillance standard for B‑cell acute lymphoblastic leukemia. The assay employs an 8–10 color antibody panel aligned with the EuroFlow consortium protocol, enabling the detection of one leukemic cell among 10,000 normal marrow cells. This level of sensitivity is critical for early identification of molecular relapse and for making timely decisions regarding treatment intensification, stem cell transplantation, or enrollment in clinical trials.
| Feature | Multiparametric Flow Cytometry (MFC) | Allele‑Specific Oligonucleotide PCR |
|---|---|---|
| Sensitivity (Limit of Detection) | 0.01% (10⁻⁴) with 8–10 color panels | 0.001% (10⁻⁵) but requires baseline clonal marker |
| Turnaround Time | Next working day (sample by 9 AM) | 3–5 working days |
| Sample Stability | Optimized cold‑chain (18–22°C); no freezing | Often requires immediate processing or RNA later |
| Clinical Applicability | >95% of B‑ALL patients; standardized against EuroFlow consortium | Requires patient‑specific primers; not always feasible in relapse |
| Regulatory Alignment | ISO 9001:2015 certified; DHA facility license 1143 | Varies by provider; may lack on‑site UAE accreditation |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA Registration ID: 61713011): “Achieving MRD negativity after induction remains one of the most powerful independent predictors of durable remission in B‑ALL. However, a single low‑level result must always be contextualized with the patient’s clinical trajectory, prior immunophenotype, and recent treatments such as corticosteroids or G‑CSF. This assay functions as a dynamic guide rather than a definitive verdict. I strongly advise patients to discuss every result with their managing hematologist before any therapeutic adjustment.”
Therapeutic Stability Advisory
⚠ Medication Safety Notice
DO NOT discontinue, alter, or taper any prescribed chemotherapeutic agent, steroid, or immunosuppressant based on this MRD result without explicit instruction from your consultant hematologist/oncologist. Abrupt cessation can provoke rapid relapse or tumor lysis complications.
Exclusion Criteria & Emergency Red Flags
- Active, uncontrolled infection (fever >38.3°C) – postpone elective MRD sampling until stabilization.
- Severe thrombocytopenia (platelets <10,000/µL) without adequate transfusion support – risk of hemorrhagic shock post‑aspiration.
- Known anaphylaxis to lidocaine or heparin – use preservative‑free alternatives and inform phlebotomist.
- If patient experiences syncope, dyspnea, or severe pain post‑procedure, seek emergency medical attention immediately.
Patient FAQ & Clinical Guidance
1. What does a negative MRD result mean for my B‑ALL prognosis?
A negative MRD result (<0.01% leukemic cells) after induction chemotherapy indicates no detectable disease by the most sensitive flow‑based assay currently available. This finding correlates with a significantly reduced relapse risk and may support treatment de‑intensification under protocol, provided the clinical context and immunophenotype are concordant.
2. How should I prepare for the bone marrow aspiration procedure?
Arrange for a driver to accompany you after sedation. Provide our clinical team with the exact date and time of collection, along with all prior immunophenotype reports and a complete clinical history. This ensures accurate gating and eliminates the need for repeat sampling.
3. Can this test be used for relapse monitoring after stem cell transplant?
Yes. Post‑transplant MRD surveillance using our ISO‑accredited flow panel is recommended at designated intervals (e.g., day +30, +100) to detect impending molecular relapse at the earliest possible time point and to guide donor lymphocyte infusion decisions.
UAE Regulatory & Data Privacy Adherence
Data Protection & Clinical Governance: All diagnostic activities are conducted in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient information is encrypted, access‑controlled, and processed solely for authorized medical purposes. Clinical safety and patient consent are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our laboratory holds DHA Facility License 1143 and is ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | Minimal Residual Disease (MRD) Analysis for B‑Cell Acute Lymphoblastic Leukemia (B‑ALL) |
| Price (AED) | 1,900 AED |
| Turnaround Time | Next working day (sample received by 9 AM) |
| Sample Type / Matrix | Bone Marrow Aspirate – Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety. |
| Methodology Used | Multiparametric Flow Cytometry (MFC), 8–10 color panel, EuroFlow‑aligned |
| ICD-10-CM Code | C91.00 |
| LOINC Code | 96578-2 |
| DHA Facility License & Laboratory Address | License: 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians